GRI Bio, Inc. (GRI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 61/100 (HIGH), 13.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.92% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
- GRI Bio Featured in "Why Now" On-Demand Video Webcast
- GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
- GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
- GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
- GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
- GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
- Grainger H1 Earnings Call Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Aerobic Exercise Training Leads to MASH Resolution as Defined by the MASH Resolution Index. — Dig Dis Sci 2026 Feb PMID 40900364
- Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitis. — Hepatology 2024 Jul 1 PMID 38112484
- Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis. — Liver Int 2024 Feb PMID 38014619
- Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis. — Nutrients 2023 Mar 20 PMID 36986211
- Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. — JHEP Rep 2023 Apr PMID 36866389
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for GRI Bio, Inc..
Full GRI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.